October 28, 2019 11:00 AM EDTUpdated October 29, 04:55 AM
Pharma
FDA+

Al­ler­gan ties up Na­men­da loose ends with $750M set­tle­ment

Natalie Grover

Reporter

Al­ler­gan, which is in process of be­ing swal­lowed by Ab­b­Vie, is clear­ing out the cob­webs. On Mon­day, it agreed to pay $750 mil­lion to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

A service from the Financial Times